Wnt/β-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer

One of the most encouraging developments in oncology has been the success of BRAF inhibitors in BRAF-mutant melanoma. However, in contrast to its striking efficacy in BRAF-mutant melanomas, BRAF inhibitor monotherapy is ineffective in BRAF-mutant colorectal cancer. Although many studies on BRAF inhibitor resistance in colorectal cancer have focused on mechanisms underlying the reactivation of the EGFR/RAS/RAF/MEK/ERK pathway, the current study focuses on identifying novel adaptive signaling mechanisms, a fresh angle on colorectal cancer resistance to BRAF inhibition. We found that treatment with BRAF inhibitors (both current and next-generation BRAF inhibitors) upregulated the Wnt/β-catenin pathway in BRAFV600E-mutant colorectal cancer cell lines through activating the cytoplasmic tyrosine kinase focal adhesion kinase (FAK). The results showed that FAK activation upon BRAF inhibitor treatment did not require EGFR or ERK1/2 activation, implying that BRAF inhibitor treatment-induced hyperactivation of Wnt signaling is “pathway reactivation”-independent. BRAF inhibition–induced Wnt pathway activation was further validated in preclinical models of BRAFV600E-mutant colorectal cancer, including cell line xenograft model and a patient-derived xenograft model. Combined inhibition of BRAF/Wnt pathways or BRAF/FAK pathways exerted strong synergistic antitumor effects in cell culture model and mouse xenograft model. Overall, the current study has identified activation of the Wnt/β-catenin pathway as a novel fundamental cause of colon cancer resistance to BRAF inhibition. Our results suggest that although complete vertical pathway blockade is pivotal for effective and durable control of BRAF-mutant colorectal cancer, cotargeting parallel adaptive signaling—the Wnt/β-catenin pathway—is also essential. Mol Cancer Ther; 17(4); 806–13. ©2017 AACR.

[1]  K. Smalley,et al.  The role of phenotypic plasticity in the escape of cancer cells from targeted therapy. , 2016, Biochemical pharmacology.

[2]  V. Sondak,et al.  Activity-Based Protein Profiling Shows Heterogeneous Signaling Adaptations to BRAF Inhibition. , 2016, Journal of proteome research.

[3]  M. Jackson,et al.  Cancer Stem Cell Plasticity Drives Therapeutic Resistance , 2016, Cancers.

[4]  James Tsai,et al.  RAF inhibitors that evade paradoxical MAPK pathway activation , 2015, Nature.

[5]  Xiwen Ma,et al.  Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers. , 2015, Cancer cell.

[6]  D. Schlaepfer,et al.  FAK/PYK2 promotes the Wnt/β-catenin pathway and intestinal tumorigenesis by phosphorylating GSK3β , 2015, eLife.

[7]  J. Ji,et al.  BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers , 2015, Molecular Cancer Therapeutics.

[8]  R. Corcoran.  New therapeutic strategies for BRAF mutant colorectal cancers. , 2015, Journal of gastrointestinal oncology.

[9]  C. Atreya,et al.  Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC). , 2015 .

[10]  Erik Sahai,et al.  Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling , 2015, Cancer cell.

[11]  M. Todaro,et al.  Colorectal cancer stem cells: from the crypt to the clinic. , 2014, Cell stem cell.

[12]  P. Queirolo,et al.  Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma , 2014, Oncotarget.

[13]  Hans Clevers,et al.  LGR5 positivity defines stem-like cells in colorectal cancer. , 2014, Carcinogenesis.

[14]  H. Clevers.  The Intestinal Crypt, A Prototype Stem Cell Compartment , 2013, Cell.

[15]  Shuxia Zhao,et al.  Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. , 2013, Cancer discovery.

[16]  R. Moon,et al.  Wnt/β-Catenin Signaling and AXIN1 Regulate Apoptosis Triggered by Inhibition of the Mutant Kinase BRAFV600E in Human Melanoma , 2012, Science Signaling.

[17]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[18]  M. Tzardi,et al.  BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients’ outcome , 2010, British Journal of Cancer.

[19]  Louis Vermeulen,et al.  Wnt activity defines colon cancer stem cells and is regulated by the microenvironment , 2010, Nature Cell Biology.

[20]  M. Belvin,et al.  Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. , 2009, Cancer research.

[21]  R. Moon,et al.  Activated Wnt/ß-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model , 2009, Proceedings of the National Academy of Sciences.

[22]  N. Kondo,et al.  miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer. , 2009, Cancer research.

[23]  Hong Wu,et al.  Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomas , 2008, Molecular Cancer Therapeutics.

[24]  Matthew D. Wessel,et al.  Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. , 2008, Cancer research.

[25]  Hong Ma,et al.  A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[26]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[27]  D. Sargent,et al.  Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. , 2015, Gastroenterology.

[28]  P. Laird,et al.  Association between molecular subtypes of colorectal cancer and patient survival. , 2015, Gastroenterology.

[29]  R. Moon,et al.  Wnt / b-Catenin Signaling and AXIN 1 Regulate Apoptosis Triggered by Inhibition of the Mutant Kinase BRAFV 600 E in Human Melanoma , 2012 .

[30]  C. Nguyên,et al.  A small molecule inhibitor of -cateninCREB-binding protein transcription , 2004 .